daunorubicin has been researched along with homoharringtonine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 10 (47.62) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Baccarani, M; Candoni, A; Damiani, D; Marie, JP; Melli, C; Michelutti, A; Michieli, MG; Russo, D; Zhou, DC; Zittoun, R | 1 |
| Benderra, Z; Manfait, M; Morjani, H; Trussardi, A | 1 |
| Bian, S; Luo, M; Xue, Y | 1 |
| Dubrulle, S; Faussat, AM; Legrand, O; Majdak, P; Marie, JP; Marjanovic, Z; Marzac, C; Tang, R | 1 |
| Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B | 1 |
| Hao, Y; Li, R; Xiao, Z; Xue, H; Yu, M; Zhang, L | 1 |
| Bian, S; Liu, S; Meng, Q; Mi, Y; Wang, J; Xue, Y; Yu, W; Zhao, Y | 1 |
| Huang, BT; Liu, XL; Xiao, Z; Yu, J; Zeng, QC; Zhu, HQ | 1 |
| Chen, J; Gu, L; Liu, Y; Pan, C; Tang, J; Xue, H | 1 |
| Chen, X; Yang, W; Zhu, X | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Deng, Z; Ding, B; Li, Y; Shi, Y; Zho, J | 1 |
| Iacoboni, G; Montesinos, P; Sanz, MA | 1 |
| Su, YZ; Sun, NT; Wang, CB; Zhou, Y | 1 |
| Fang, L; Hu, N; Lin, Y; Pan, L; Qin, T; Qu, S; Ru, K; Wang, J; Xiao, Z; Xing, R; Xu, Z; Zhang, H; Zhang, Y | 1 |
| Gong, BF; Gong, XY; Gu, RX; Li, W; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Wang, JX; Wang, JY; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhao, XL; Zhou, CL | 1 |
| Dang, FT; Wan, YM; Yang, J; Yang, QJ; Zheng, J | 1 |
| Braniecki, M; Gok Yavuz, B; Hwang, J; Quigley, JG; Singh, N; Tsoukas, MM | 1 |
| Feng, X; Gao, X; Li, H; Liu, Q; Luo, L; Mao, S; Yang, P; Zhang, D | 1 |
| Fang, QY; Gong, BF; Gong, XY; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Qiu, SW; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, CX; Zhang, GJ; Zhou, CL | 1 |
1 review(s) available for daunorubicin and homoharringtonine
| Article | Year |
|---|---|
Conventional induction and post-remission therapy in APL: have we arrived?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Mitoxantrone; Multicenter Studies as Topic; Oxides; Remission Induction; Tretinoin | 2014 |
4 trial(s) available for daunorubicin and homoharringtonine
| Article | Year |
|---|---|
High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.
Topics: Aged; Antineoplastic Agents; China; Daunorubicin; Female; Harringtonines; Homoharringtonine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models | 2012 |
Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells.
Topics: Adolescent; Adult; Antigens, CD34; Antigens, CD7; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cell Count; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Harringtonines; Hematologic Diseases; Homoharringtonine; Humans; Immunophenotyping; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Remission Induction; Young Adult | 2014 |
[Homoharringtonine in newly diagnosed acute promyelocytic leukemia treatment: a prospective, randomized controlled trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Daunorubicin; Disease-Free Survival; Harringtonines; Homoharringtonine; Humans; Incidence; Leukemia, Promyelocytic, Acute; Leukocyte Count; Neoadjuvant Therapy; Platelet Transfusion; Prospective Studies; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 2016 |
Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cyclophosphamide; Cytarabine; Daunorubicin; Down-Regulation; Drug Eruptions; Hidradenitis; Homoharringtonine; Humans; Incidence; Leukemia, Myeloid, Acute; Mercaptopurine; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neutrophils; Protein Kinase Inhibitors; Sweat Glands | 2021 |
16 other study(ies) available for daunorubicin and homoharringtonine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colonic Neoplasms; Cyclosporins; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Gene Amplification; Harringtonines; Homoharringtonine; Humans; Leukemia-Lymphoma, Adult T-Cell; Neoplasm Proteins; Tumor Cells, Cultured; Verapamil; Vinblastine | 1995 |
Characterization of H+-ATPase-dependent activity of multidrug resistance-associated protein in homoharringtonine-resistant human leukemic K562 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Buthionine Sulfoximine; Cell Survival; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Harringtonines; Homoharringtonine; Humans; K562 Cells; Kinetics; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Proton-Translocating ATPases; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 1998 |
[Study on combined chemosensitivity test in acute non-lymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1998 |
Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspase Inhibitors; Caspases; Cytarabine; Cytochromes a; Cytochromes c; Daunorubicin; Down-Regulation; Harringtonines; HL-60 Cells; Homoharringtonine; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proteasome Inhibitors; Protein Biosynthesis; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2 | 2006 |
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine | 2006 |
The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis | 2008 |
Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Harringtonines; Homoharringtonine; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis | 2008 |
Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; China; Clinical Chemistry Tests; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Harringtonines; Hematologic Tests; Hepatitis B; Homoharringtonine; Humans; Infant; Leukemia, Myeloid, Acute; Liver Failure; Male; Pancreatitis; Remission Induction; Secondary Prevention | 2011 |
Successful treatment of childhood Philadelphia chromosome-positive acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Cytarabine; Daunorubicin; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Piperazines; Pyrimidines | 2011 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Case-Control Studies; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Endostatins; Female; Fibroblast Growth Factors; Gene Expression; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; ROC Curve; Treatment Outcome | 2015 |
[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Topics: Cytarabine; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Acute pancreatitis induced by combination chemotherapy used for the treatment of acute myeloid leukemia: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dasatinib; Daunorubicin; Female; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Pancreatitis; Tomography, X-Ray Computed | 2020 |
Co-Delivery of Daunorubicin and Homoharringtonine in Folic Acid Modified-Liposomes for Enhancing Therapeutic Effect on Acute Myeloid Leukemia.
Topics: Cell Line, Tumor; Daunorubicin; Folic Acid; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Liposomes | 2023 |
[Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Nuclear Proteins; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2022 |